Anti-BCMA-engineered exosomes for bortezomib-targeted delivery in multiple myeloma.

ABSTRACT:

Abstract

Exosomes have emerged as promising vehicles for delivering therapeutic cargoes to specific cells or tissues, owing to their superior biocompatibility, reduced immunogenicity, and enhanced targeting capabilities compared with conventional drug delivery systems. In this study, we developed a delivery platform using exosomes derived from monocytes, specifically designed for targeted delivery of bortezomib (Btz) to multiple myeloma (MM) cells. Our approach involved the genetic modification of monocytes to express antibodies targeting B-cell maturation antigen (anti-BCMA), because BCMA selectively expresses on myeloma cells. This modified anti-BCMA was then efficiently incorporated into the monocyte-derived exosomes. These adapted exosomes effectively encapsulated Btz, leading

SUBMITTER: Yuan S 

PROVIDER: S-EPMC11421322 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature